Good day, welcome to the Asensus Surgical First Quarter Financial and Operating Results conference call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touch-tone phone. To withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Mark Klausner. Please go ahead. Good afternoon, everyone, and thank you for joining us for the Asensus Surgical First Quarter 2023 Business and Financial Update conference call. On the call with me today are Anthony Fernando, President and Chief Executive Officer, and Shameze Rampertab, Chief Financial Officer. Before we begin, I would like to caution listeners that certain information discussed by management during this conference call, including any guidance provided, are forward-looking statements covered under the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those stated or implied by our forward-looking statements due to risks and uncertainties associated with the company's business, including any geopolitical factors beyond our control. The company undertakes no obligation to update the information provided on this call. For a discussion of risks and uncertainties associated with the Asensus Surgical business, I encourage you to review the company's filings with the Securities and Exchange Commission, including the 2022 Form 10-K filed in March 2023 and the Form 10-Q expected to be filed later today, and any other filings we make with the SEC. During this call, we will also present certain non-GAAP financial information related to adjusted net loss attributable to common stockholders and the adjusted net loss per share attributable to common stockholders. Management believes that these non-GAAP financial measures, taken in conjunction with U.S. GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company's core operating results. Management uses non-GAAP financial measures to compare our performance relative to forecast and strategic plans, to benchmark outperformance externally against competitors, and for certain compensation decisions. Reconciliations from U.S. GAAP to non-GAAP results are presented in the tables accompanying our earnings release, which can be found in the investor relations section of our website. With that, it's my pleasure to turn the call over to Asensus Surgical's President and Chief Executive Officer, Anthony Fernando. Thanks, Mark, and thank you all for joining us today. I will begin by discussing our recent performance and highlights. Shameze will review our financial results. Following that, I will go over our priorities for the balance of 2023 before turning to Q&A. The first quarter was highly productive at Asensus. We made significant progress across a number of our key areas of focus, including the expanded utilization of Senhance, the continued development of our clinical body of evidence, and the ongoing development of our portfolio. In addition, we had a number of very exciting announcements. In particular, the unveiling of our LUNA Surgical System that is in development. During the first quarter, we continued to see very positive procedure volume trends, with over 900 procedures across multiple specialties and geographies delivering 20% year-over-year growth. Procedure volume is critical as we look to expand and optimize our digital surgery capabilities. The larger our collection of surgical data, the more effective our machine learning engine becomes, which will enable us to continue to deliver more clinical intelligence to surgeons through the ISU. Another benefit of increased procedure volumes is the expansion of our clinical registry, which now includes over 2,400 patients. The primary purpose of this registry is to build a unique collection of intra operative and 12-month postoperative follow-up data, which will support an increased number of high-quality clinical publications and further bolster our market development strategy. Moving to new program initiations. Year to date, we have initiated one new Senhance program which was in Japan. Japan continues to be one of our fastest-growing regions, and we are excited to be expanding our partnerships with some of the region's leading institutions. Most recently, we initiated a program at Fukuoka Tokushukai Hospital in Kasuga City. We are delighted to see positive feedback from customers and look forward to supporting the continued adoption throughout the region moving forward. On the portfolio development front, we had multiple achievements. Early in Q1, we obtained CE mark approval for the expanded machine vision capabilities with the ISU, which continues to receive high praise across the industry. The ISU was recently honored with two prestigious awards. The first from MedTech Breakthrough, where the ISU was named the best new technology solution in the surgical category. This is a remarkable achievement as we competed against nearly 4,000 nominations from across the globe. It reflects our commitment to pushing the boundaries of innovation in the medical technology industry. The second comes from Future Digital Awards for Digital Health Innovation, where our ISU has been honored as the best medical robotic solution and awarded the platinum winner title. These recognitions are testament to the outstanding capabilities and potential of our ISU in revolutionizing the field of surgical robotics and digital surgery. The ISU integrated with the Senhance system is the only real-time solution on the market today that provides surgeons with a suite of tools to use during their surgical procedures, which includes eye-tracking camera control, haptic feedback, digital measurement, and digital tags. Eye tracking allows surgeons to seamlessly control the camera position without pausing the procedure. There are also digital tags that enhance the communication between the surgeon at the console and the OR team bedside to further engage and support a seamless operating room experience. Digital measurement tools enabled by the ISU allow surgeons to digitally quantify distances and measure over the contour of the anatomy to support intraoperative surgical planning and decision-making. In late March, we attended this year's Society of American Gastrointestinal and Endoscopic Surgeons, or SAGES conference. We had an outstanding conference with tremendous interest in Senhance and the ISU. To kick off SAGES, we hosted a moderated broadcast of a live Senhance surgery performed in Germany by Dr. Viviane Dommermuth to a packed breakfast symposium from the conference in Montreal. This event demonstrated the capabilities of both our Senhance system and ISU, as well as our telepresence capabilities with Senhance Connect. Interest from this full room led to strong attendance at our booth, where we also hosted multiple sessions focused on the Asensus capability to deliver augmented intelligence in surgery through our ISU platform. Finally, with the importance of the underserved pediatric market, we had a special focus on engaging key pediatric surgeons. We hosted an event with several U.S. pediatric surgeons to better understand their needs for this unique specialty. We also attended the German Congress of Surgery 2023, or DCK, hosted in Munich, Germany. During this event, similar to SAGES, we hosted a live surgery in which Senhance and the ISU drew a great deal of attention from more than 100 attendees. This led to a fully booked agenda of hands-on demonstration for surgeons to have individual dedicated time to learn more and experience the Senhance system and the digital ISU tools. To continue the focus on the pediatric market and expand on our learnings from SAGES, we hosted a group of key European pediatric surgeons to better understand their needs and how we can support further research for this specialty. We will continue this focus into next quarter at the IPEC and ESPES, International Pediatric Endoscopy Group and European Society of Paediatric Endoscopic Surgeons joint global meeting in Italy this summer. Turning to other recent developments. As we unveiled during our Investor Day in February, we are incredibly excited about our next generation LUNA system, which is currently in development. LUNA was developed over the course of nearly four years with input from surgeons, OR teams, strategic partners, and hospital administration. We encourage you to watch the entire Investor Day webcast to learn about the unique combination of hardware and software that we believe enhances safety, reliability, performance, and scalability. In February, we disclosed we had signed a memorandum of understanding with Karl Storz, a major player in the surgical device industry. The definitive agreements are progressing towards signing and will represent an important step expanding our commercial reach and development capabilities. Upon completion, it will enable Asensus to bring the benefits of the ISU to Karl Storz extensive global customer base. Both organizations are working diligently to finalize the agreements as quickly as possible. Before turning the call over to Shamez, I wanted to highlight our continued efforts to expand our presence in the pediatric space. As we have discussed at length on previous calls, the combination of Senhance's 3mm instrumentation, haptic feedback, and the ISU's clinical intelligence make the platform uniquely effective at performing pediatric procedure. After having received a pediatric CE mark in 2020, we received FDA 510,000 clearance for a U.S. pediatric indication in March of this year. With this FDA clearance, we now have the ability to help surgeons deliver better outcomes globally. We have also been hard at work to develop pediatric specific real-world data. During the first quarter, a paper was published that detailed early experience utilizing our Senhance platform in pediatric procedures in the U.S. This study conducted with IRB approval prior to 510(k) clearance, showcases the safety and feasibility of using Senhance in pediatric cases. The surgical team successfully performed surgeries on patients ranging from 4 months to 16 years of age. These procedures included gallbladder removal, hernia repair, and other types of urological and GI procedures. These early results highlight the potential of our platform in the pediatric population and further validate its safety and effectiveness. We have continued to see increased interest in using Senhance and the ISU specifically for pediatrics. As we announced during the fourth quarter, we installed a system in Germany to be used exclusively with their pediatric surgery department. We believe that there is a significant opportunity to bring all of the benefits of Performance-Guided Surgery to a largely underserved pediatric market, which will continue to be a focus of our expansion efforts to meet the increasing demand. In summary, I'm thrilled with the breadth of our accomplishments during the first quarter and how we have positioned ourselves for long-term success. With that, I will turn the call over to Shamez for a financial update. Thanks, Anthony. Turning to the first quarter for the 3 months ended March 31, 2023, the company reported revenue of $1 million as compared to revenue of $1.1 million in the 3 months ended March 31, 2022. Revenue in the first quarter of 2023 included $0.5 million in lease revenue, $0.3 million in instruments and accessories, and $0.2 million in services. For the 3 months ended March 31, 2023, total operating expenses were $20.4 million as compared to $18.2 million in the three months ended March 31, 2022. For the three months ended March 31, 2023, net loss attributable to common stockholders was $22.2 million or $0.09 per share, as compared to a net loss attributable to common stockholders of $19.1 million or $0.08 per share in the three months ended March 31, 2022. For the three months ended March 31, 2023, the adjusted net loss attributable to common stockholders was $22 million or $0.09 per share, as compared to an adjusted net loss of $16.6 million or $0.07 per share in the three months ended March 31, 2022. Adjusted net loss is GAAP net loss, adjusted for the following items: amortization of intangible assets and change in fair value of contingent considerations, both of which are non-cash charges. Adjusted net loss attributable to common stockholders is a non-GAAP financial measure. Reconciliation from GAAP to non-GAAP measures can be found in our earnings release. Turning to the balance sheet, the company had cash equivalents, short-term and long-term investments, excluding restricted cash of approximately $57.4 million as of March 31, 2023. I'll turn the call back over to Anthony. Thanks, Shamez. Turning to the balance of 2023 and what we expect to achieve during the back half of the year. Starting with the Luna program, we have completed much of the R&D over the last few years and are moving quickly into testing and evaluation ahead of regulatory filings. In the second half of 2023, we will have surgeons perform system tests to provide feedback before completing preclinical evaluations of the fully built system by the end of the year. During the first half of 2024, we'll freeze the system's design, complete verification and validation testing, and ramp up our manufacturing capabilities. By the end of 2024, we intend to submit to the FDA and other regulatory bodies in Europe and Japan with the expectation of receiving FDA clearance in mid-2025. We will move into a commercial pilot launch during the second half of 2025. We are confident in our progress towards the commercial launch of these systems. We'll continue to provide updates as we move forward. As it relates to Senhance, we continue to expect to initiate 10 to 12 new Senhance programs during 2023. Additionally, we expect procedure volume growth for the rest of 2023 to track similarly to what we saw in the first quarter. The data collected through these procedures has been instrumental. As additional sites utilize the ISU in the coming months, it will increase the data we can leverage. The data collection nearly tripled sequentially. We hope to have more than half of our sites using the ISU by the fourth quarter. With this level of data collection, we will be able to continue to drive innovation and make significant advancements in Performance-Guided Surgery. These are exciting times at Asensus. We have continued to push the boundaries of what's possible in robotic surgery, and we will keep pushing to deliver the tools and capabilities that surgeons need to deliver better, more consistent outcomes for their patients. I want to thank our global team for their hard work and dedication to make this truly novel technology a reality. Before turning to Q&A, I wanted to remind investors about details of our upcoming annual stockholders meeting, which will be held virtually on June 6, 2023. For more information on how to access the meeting and what matters will be discussed, please see our annual proxy statement, which was filed at the end of April. With that, I would like to open the line for Q&A. Thank you. We will now begin the question and answer session. To ask a question, you may press star then one on your touchtone phone. If you are using a speakerphone, we ask that you please pick up your handset before pressing the keys. To withdraw your question, please press star then two. Today's first question comes from Ross Osborn with Cantor Fitzgerald. Please go ahead. Hi, guys. Congrats on your industry recognitions and progress, and thanks for taking my questions. Starting off, you know, is there any more feedback on a pediatric launch you could provide? Do you think this could drive an inflection in your system placements? Hey, Ross. Just to talk about pediatrics, you know, we have been speaking with U.S. accounts for some time now, and we couldn't, you know, we were not very active until we got the approval. Since then, there's definitely interest, which we saw at SAGES, and we've been following up on those to see how we might be able to start additional programs. Also in Europe, that's growing. We started, as you know, with one site. Now we are up to two sites and soon be three. Also in Japan, there's been interest. Definitely there's no shortage of interest. It's about trying to get the sites organized and some of the early adopters of this technology connected so that they can speak to each other before they start their program. Overall, I think there is an opportunity. It is a unique solution because there is given the instrumentation and the haptic feedback that we offer, I think it'll truly be differentiated within robotics, and to have some meaningful share for this Senhance system in pediatrics. Great. Thank you. Maybe one for Shameze. A large step on R&D sequentially in YoY. Could you just walk through some of the drivers there? You know, I imagine part of it's due to LUNA, but I thought that had already come into the model during the fourth quarter. Yeah. Thanks for your question, Ross. With regards to Q1 tends to be a heavier quarter for us in terms of burn in general when you look at the seasonality YoY. In Q1 of this year, we did spend a lot of effort in terms of getting ready with our investor event and making sure Luna was ready for the unveil, which we had at our investor event. We continue to work towards the milestones that Anthony laid out on Luna. Also, we disclosed that we are working towards a standalone ISU. We currently have the Intelligent Surgical Unit that's approved in U.S., Europe, and Japan, but that is integrated into Senhance. This will be a standalone ISU. A lot of great projects that we're working towards. But Q1 should not be indicative of the rest of the quarter in terms of that burn rate. Got it. Thanks for taking my questions. Thank you. Our next question today comes from Yi Chen with H.C. Wainwright. Please go ahead. Hello, Anthony and Shameze. Can you hear me? Yeah. Go ahead, Yi. Yes. Thanks for taking my question. I just want to get a feel of the potential market size in the pediatric patient. Is it like, one-tenth of the adult surgery volume or what's the percentage there? Another question is, do you anticipate to use the same sales force or are you expecting to add additional pediatric, specialty sales force there? Thank you. Thanks for the questions, Yi Chen. I think trying to answer the market size, I mean, I can tell you, approximately it's somewhere between 3 million to 4 million procedures, if you just look at the U.S. It's kind of hard to give you a definite number because there's not a whole lot of data available. In terms of scale, I would say 3 million to 4 million is a reasonable assumption with respect to market size. With respect to the sales force, I think, you know, you need before we really push hard on the commercial front, I think the goal for us is to really get a few pilot sites up and running and get some early data published. I think we will use our existing clinical sales team and our existing commercial teams to help us move this forward. That said, I do wanna clarify that we do have in Europe, and also we'll be developing this in Japan, but there's some clinical support staff that have, you know, performed a lot more on the pediatric side who tend to focus more on pediatric support of hospitals. There's a little bit of specialization, but for the most part, it'll be the existing team that will support the expansion into pediatric. Okay. Thanks for the answer. That's very helpful. Thank you. Our next question comes from Swayampakula Ramakanth with H.C. Wainwright. Please go ahead. Thank you. Good afternoon, Shameze and Anthony. I apologize if some of these questions have been already asked. Just trying to get a sense of where you are with the LUNA Surgical System, especially in terms of preclinical evaluation and also some of the testing that you plan to do for the you know, during this year. Sure, RK. I think the goal for this year, like we've stated, we kinda have two milestones. The year-end milestone is really try to do a full system test in a preclinical setting so that we can make sure that end-to-end the system is delivering on the performance criteria. Throughout the year, we intend to bring in surgeons and perform some work using either tissue models or even it could even be small scale preclinical to gather feedback and also make it more of a testing kind of a platform for, you know, goes both ways, right? We need to know what the surgeons think and also from a development point of view, we know that the solution is robust. I would say, you know, towards the middle of the year would be one milestone where we get surgeons and get feedback to further develop, and that will help us lead into the year-end milestone of doing a full system preclinical evaluation. When do you need to do any sort of clinical testing as such before or what, basically what is the regulatory pathway? I think that's the question I have. Yeah. I think, for us, we intend to follow a traditional 510,000, because we are a predicate. That's the current path we follow. Then, on the Karl Storz, I know, you're still working on this relationship. Can you give any additional color as to how close you are or, you know, what else needs to get done before, both parties can sign on the dotted line? Yeah. I think great question, RK. It's a extremely complicated agreement as you can imagine. You know, there is IP involved, there's R&D component, there's manufacturing, then there's a whole business, commercial aspect and regulatory, all being discussed on a global scale. It's not just for the U.S., it's for U.S., Europe and Asia. There are a lot of complexities and a lot of conversations going on. Both companies are very diligently working to try to wrap it up as soon as possible. I'd say that, you know, progress is made, and as soon as we get it finalized, we'll make sure we communicate that. Perfect. Thank you very much, Anthony. Good luck, and talk to you soon. Thanks, RK. Thank you. Ladies and gentlemen, this concludes our question and answer session. I'd like to turn the conference back over to the management team for any final remarks. Thank you, operator. Thanks again for joining us today and for your support of Asensus. We look forward to updating you on our next quarterly call. Thank you. Ladies and gentlemen, this concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.